Swedish Orphan Biovitrum AB (publ)
STO:SOBI
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Swedish Orphan Biovitrum AB (publ)
Total Receivables
Swedish Orphan Biovitrum AB (publ)
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Receivables
kr8B
|
CAGR 3-Years
23%
|
CAGR 5-Years
18%
|
CAGR 10-Years
32%
|
|
Biogaia AB
STO:BIOG B
|
Total Receivables
kr133.9m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
Hansa Biopharma AB
STO:HNSA
|
Total Receivables
kr115.5m
|
CAGR 3-Years
93%
|
CAGR 5-Years
98%
|
CAGR 10-Years
67%
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Receivables
kr162.2m
|
CAGR 3-Years
66%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Vitrolife AB
STO:VITR
|
Total Receivables
kr645m
|
CAGR 3-Years
37%
|
CAGR 5-Years
22%
|
CAGR 10-Years
24%
|
|
BioArctic AB
STO:BIOA B
|
Total Receivables
kr7.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
See Also
What is Swedish Orphan Biovitrum AB (publ)'s Total Receivables?
Total Receivables
8B
SEK
Based on the financial report for Mar 31, 2024, Swedish Orphan Biovitrum AB (publ)'s Total Receivables amounts to 8B SEK.
What is Swedish Orphan Biovitrum AB (publ)'s Total Receivables growth rate?
Total Receivables CAGR 10Y
32%
Over the last year, the Total Receivables growth was 24%. The average annual Total Receivables growth rates for Swedish Orphan Biovitrum AB (publ) have been 23% over the past three years , 18% over the past five years , and 32% over the past ten years .